Heart failure is a leading cause of morbidity and mortality worldwide, affecting more than 64 million people globally. Around 70% of heart failure cases originate from ischemic events such as myocardial infarction, which cause irreversible loss of functional cardiac tissue. Despite advances in pharmacological therapies and revascularization procedures, current treatments mainly manage symptoms and slow disease progression but fail to repair or regenerate damaged myocardium. As a result, nearly 50% of patients die within five years of diagnosis, and many experience severe limitations in mobility and quality of life. The growing prevalence of heart failure, driven by population aging and chronic disease burden, places an increasing clinical and economic strain on healthcare systems, highlighting the urgent need for effective, regenerative, and scalable therapeutic solutions.